000			04943cam a2200601 i 4500
001			ocn912875317
003			OCoLC
005			20221128212922.0
006			m d
007			cr |||||||||||
008			150323s2015 nyua ob 001 0 eng
010			_a 2020679081
040			_aDLC _beng _erda _cDLC _dN$T _dYDXCP _dEBLCP _dD6H _dOCLCF _dSTF _dAU@ _dSCB
019			_a918623642 _a957737140 _a958083084 _a963734581 _a967769860
020			_a9781634826358 _qebook
020			_a1634826353
020			_z1634825942 _qhardback
020			_z9781634825948 _qhardback
035			_a1020628 _b(N$T)
035			_a(OCoLC)912875317 _z(OCoLC)918623642 _z(OCoLC)957737140 _z(OCoLC)958083084 _z(OCoLC)963734581 _z(OCoLC)967769860
072		7	_aHEA _x039000 _2bisacsh
072		7	_aMED _x014000 _2bisacsh
072		7	_aMED _x022000 _2bisacsh
072		7	_aMED _x112000 _2bisacsh
072		7	_aMED _x045000 _2bisacsh
049			_aMAIN
245	0	0	_aPulmonary arterial hypertension and nifedipine : _bpathogenesis and management _c _h[E-Book]
264		1	_aNew York : _bNova Biomedical, _c[2015]
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
490	1		_aNew developments in medical research
504			_aIncludes bibliographical references and index.
588			_aDescription based on print version record.
505	0		_aChapter I: Mechanisms of Vascular Remodeling in Pulmonary Arterial Hypertension; Abstract; Introduction; Classification; Symptoms and Diagnosis; Biomarkers; Pathogenesis of PAH; i) Role of Endothelial Cells and Their Cross Talk with Different Cell Types in Vasculature; Endothelial Response to Injury; Endothelial Dysfunction and Vasoconstriction/Vasodilatation.
505	8		_aEndothelial Dysfunction and Impaired AngiogenesisEndothelial Dysfunction and Plexiform Lesions; ii) Role of Inflammation and Autoimmunity; Inflammatory Cells; Cytokines and Chemokines; Molecular Mechanisms Contributing to PAH-PASMC and PAEC Proliferation and Resistance to Apoptosis; The Src/STAT3 Integrative Hub; Metabolic Switch: The Warburg Effect; Epigenetic Mechanisms of PH; Role for miRNAs; DNA Methylation; Modification of Histone Proteins; Potential Implication of Long Noncoding RNA; Vascular Stiffening in PAH: A Cause; or Consequence?; Treatment.
505	8		_aBasic Measures and Conventional TherapiesApproved PAH Therapies; 1) Prostacyclin Pathway; 2) Endothelin Pathway; 3) Nitric Oxide-cGMP Pathway; New Drugs in Early Phase of Development; i) Newer Agents Targeting Established Vasodilatory Pathways; ii) Tyrosine Kinase Inhibition; iii) Serotonin System; iv) Vasoactive Intestinal Peptide; v) RhoA/Rho-Kinase Signaling Pathway; vi) Statins; vii) Apelin; viii) Anti-inflammatory therapies; ix) Restoration of BMPR-II Signaling Axis; Procedures/Nonmedical Therapies; Expected Novel Drugs in Future/ Therapies under Investigation; Gap in Knowledge.
505	8		_aIv) Neprilysin Knockout ModelOverexpression Models; i) Interleukin-6 Overexpression Model; ii) S100A4/Mts-1 Overexpression Model; Methods to Study PAH; In-vitro Methods; I. Isolation and Culture of Primary Cells; i) Human pulmonary artery endothelial cells from transplant donors; ii) Isolation of pulmonary artery smooth muscle cells; Method; Histological and Morphological Analysis; 1. Hematoxylin and Eosin (H & E) Staining; H & E Staining of Frozen Sections of Pulmonary Artery; Method; H & E Staining for Parrafin Sections of Pulmonary Artery; Method; 2. Masson's Trichrome Staining; Procedure.
520			_aPulmonary arterial hypertension (PAH) is a progressive, fatal syndrome characterized by increased vascular resistance that leads to right-ventricular hypertrophy and heart failure, eventually leading to death. The chapters of this book describe the molecular mechanisms and cellular events regulating vascular remodeling in PAH; the various animal models and drugs currently being used in various laboratories to study mechanisms leading to pulmonary arterial hypertension; and nifedipine, its pharmacology and it's role in the management of pulmonary hypertension and some of the drawbacks concernin.
590			_aMaster record variable field(s) change: 050, 082
650		0	_aPulmonary hypertension.
650		0	_aPulmonary hypertension _xChemotherapy.
650		0	_aNifedipine _xTherapeutic use.
700	1		_aEstrada, Victoria _c(Editor), _eeditor.
830		0	_aNew developments in medical research.
856	4	0	_uhttps://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=1020628 _yKingston Hospital NHS Foundation Trust OpenAthens account holders click here for access
938			_aYBP Library Services _bYANK _n12512606
938			_aEBSCOhost _bEBSC _n1020628
938			_aProQuest Ebook Central _bEBLB _nEBL2130687
942			_n0
994			_a92 _bN$T
999			_c92221 _d92221